CBIO Company Profile and Key Details

CBIO has shown sold momentum, gaining 27.32% over the past week and 11.48% over the past quarter, though year-to-date performance is up 17.88%. Short-term trend indicators are bullishly aligned (SMA20 20.06%, SMA50 8.73%, SMA200 -10.65%). The stock’s 14-day RSI is 62.01 (firm momentum), while the ATR of 0.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.52% below its high and over 41.57% above its low. Average 10-day trading volume of 204.39 thousand shares is below the 3-month average of 304.80 thousand, indicating normal recent market interest.

Crescent Biopharma, Inc. generated EPS of -$21.97 over the past year. Five-year average earnings growth is 15.18%. Wall Street analysts project EPS growth of 58.9% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $25.00. The high target offers 123.07% upside. The low target suggests 59.34% downside. The mean target is $27.17. This offers 73.17% upside. Crescent Biopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by -17.65%. The prior quarter beat by 80.63%. Over the last six quarters, Apple has recorded several small beats. These include -31.25% in February 13, 2025.

Crescent Biopharma, Inc. (NASDAQ:CBIO) closed at $15.69 USD, losing -$1.65 (-9.52%) from the previous close of $17.34. The stock is currently mid-range between its 52-week high and low $8.72 and $27.41. With a market capitalization of about $432.60 million, Crescent Biopharma, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 321.44 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Crescent Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua T. Brumm, the company employs approximately 44 people and listed since January 10, 2014. Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies.

Crescent Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.91. This means the shares are trading below this model’s fair value.

Crescent Biopharma, Inc. trades at a P/E ratio of -1.45, slightly below the S&P 500 average, with a price-to-sales ratio of 36.8 and a price-to-book ratio of 2.62 suggesting the stock is closer to book value. The P/FCF stands at -3.06, also above market averages.

Our AI price prediction model suggests that Crescent Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.27%, with price expected at $15.49 by July 27, 2026, within a range of $14.64 to $16.34 3-Month Outlook: Projected fall of -30.85%, reaching $10.85 by October 08, 2026, with a range of $10.54 to $11.18. 1-Year Outlook: Projected gain of 48.12%, with price at $23.24 by July 13, 2027, within a range of $21.91 to $24.32.

Crescent Biopharma, Inc. (NASDAQ:CBIO) shares are up 17.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Crescent Biopharma, Inc. trading at a premium to the broader market with a P/E of -1.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.47, suggesting 62.33% upside. Our AI forecast model points to short-term weakness (-1.27% over two weeks), a medium-term fall (-30.85% over three months), and a longer-term gain (48.12% over one year), with expected trading ranges indicating moderate volatility.